Featured Post from ChristianaCare

Researchers Discover That Cancer Stem Cell Populations in Colorectal Cancers Are Diverse, Not Uniform

Apr 4, 2023

4 min

Discovery may lead to more precise treatments for advanced colorectal cancer


Researchers at ChristianaCare’s Cawley Center for Translational Cancer Research at the Helen F. Graham Cancer Center & Research Institute have demonstrated for the first time that microRNA (miRNA) expression leads to a diversity of cancer stem cells within a colorectal cancer tumor. This diversity of cancer cells may explain why advanced colorectal cancer is difficult to treat. Study results have been in the Journal of Stem Cell Research and Therapy.


The findings broaden the understanding of how miRNA expression adds to cancer stem cell diversity and may lead to more precise anti-cancer treatments for patients with advanced colorectal cancer. The research builds on prior discoveries by scientists at the Graham Cancer Center about how cancer stem cell activity contributes to the development and spread of colorectal cancer.


“Our research shows — at least in the laboratory — that there are different subpopulations of cancer stem cells in a tumor, and they may be driving the growth of the cancer,” said Principal Investigator Bruce Boman, M.D., Ph.D., MSPH, FACP, medical director of Cancer Genetics and Stem Cell Biology at the Graham Cancer Center. “In one subpopulation of cancer stem cells, its miRNA will shut down the stem cell genes that are expressed in another subpopulation, and vice versa, within the same tumor.”


From left: ChristianaCare researchers Lynn Opdenaker, Ph.D., Brian Osmond, Bruce Boman, M.D., Ph.D., Chi Zhang, Victoria Hunsu, Caroline Facey, Ph.D. Not pictured Victoria Stark, MS.


The study focused on the composition of cancer stem cells within a colorectal cancer cell line (HT29) in the laboratory setting. Researchers evaluated the different cancer stem cell subpopulations that were identified by examining patterns of miRNA expression in each subpopulation and looking for differences. The researchers found that each of the four diverse subpopulations that were studied (ALDH, LRIG1, CD166 and LGR5) had a different miRNA expression or gene signature.


The researchers found that miRNA expression could inhibit the expression of messenger RNA (mRNA), which carries instructions from the DNA to encode specific proteins within cells. Therefore, miRNA, by controlling gene expression, dictate which proteins are contained in the stem cells. The researchers discovered the miRNA that are upregulated in certain cancer stem cell subpopulations are downregulated in other cancer stem cell subpopulations. In this way, differential miRNA expression leads to cancer stem cell heterogeneity within colorectal tumor tissue.


“It’s an early research finding and needs to be followed up with other experiments, but it has clear relevance to the clinic,” Boman said. “The question is: Can you target the miRNA to make cancer more sensitive to certain treatments? Because we know what the current anti-cancer treatments are targeting, we may be able to modulate or manipulate the cancer, so it becomes more sensitive to the treatment.”


Identification of a network of genes regulated by microRNAs in a cancer stem cell subpopulation.



For more than a decade, ChristianaCare’s researchers have contributed to the understanding of the role that cancer stem cells and miRNA expression play in the development and spread of colorectal cancer. This latest finding builds on earlier discoveries that examined a link between two cellular signaling pathways: retinoic acid (RA) signaling and wingless-related integration site (WNT) signaling, which are dysregulated by different gene mutations in colorectal tumors.


The RA signaling pathway induces growth arrest and differentiation of cancer stem cells. Notably, retinoic acid is effective against other types of cancer such as leukemia. The role of the WNT signaling pathway has an opposite effect on tumor growth. The WNT signaling pathway is activated by a mutation in the APC (adenomatous polyposis coli) gene in about 90% of cases of colorectal cancer. In APC mutant tissue, dysregulated miRNA expression may underlie an imbalance between the RA and WNT signaling, which then leads to intratumoral cancer stem cell heterogeneity. Still, this mechanism that may enable the cancer to proliferate could also provide clues on how to more effectively treat cancer.


“If you’ve got an imbalance between these two signaling pathways, then you’ve likely got a growth driver,” Boman said. “The question is: Can you suppress the WNT signaling and enhance the retinoic acid signaling?”


It may be possible to increase the sensitivity of colorectal cancer to retinoic acid-type drugs, and therapeutically shift the balance between different cancer stem cell subpopulations, thereby suppressing cancer growth. More research is needed to determine how targeted cancer therapies containing retinoic acid-type drugs may be made more effective against advanced cancer.


This research will be presented at the annual meeting of the American Association for Cancer Research in Orlando, Florida, April 14-19.


This research project was supported by a grant from the Lisa Dean Moseley Foundation.

You might also like...

Check out some other posts from ChristianaCare

2 min

Maureen Leffler, D.O., Named ChristianaCare’s Chief Wellbeing Officer

Maureen “Mo” Leffler, D.O., MPH, has been appointed chief wellbeing officer of ChristianaCare, effective Nov. 25. In her role, Leffler leads the ChristianaCare Center for WorkLife Wellbeing and strategies to enhance the professional fulfillment and well-being of ChristianaCare’s nearly 14,000 caregivers, overseeing advocacy programs and initiatives to optimize their experience and foster a culture of well-being throughout the organization. She works closely with leaders across key departments to address factors impacting caregiver well-being. Leffler most recently served as the inaugural chief wellbeing officer at Nemours Children’s Health, where she helped the organization to achieve the 2022 Joy in Medicine distinction from the American Medical Association for prioritizing proven efforts to enhance the professional fulfillment of physicians. There, she established a Center for Associate Wellbeing; led the first systemwide assessment to strategically address well-being and burnout; and implemented a peer support program and expanded the scope of resources available to support the emotional and mental health needs of employees. In collaboration with organizational leaders, she supported targeted clinical team assessments and systems-based interventions to foster well-being. Prior to this role, Leffler served as a pediatric rheumatologist at Nemours and as an assistant professor of pediatrics in the Division of Rheumatology at Thomas Jefferson University. Since 2017, Leffler has served as the course director of the Chief Resident Leadership Training Program for the Accreditation Council for Graduate Medical Education (ACGME). In response to the COVID-19 outbreak, she co-chaired ACGME’s National Task Force on Well-Being. She and her team developed a national graduate medical education well-being community, which she continues to convene, to understand the evolving challenges and share strategies to improve well-being. She represents the ACGME as a coach for the National Academy of Medicine Action Collaborative on Clinical Well-Being and Resilience. She also serves as a consultant to the Professional Satisfaction team at the American Medical Association. Leffler earned her medical degree from the Philadelphia College of Osteopathic Medicine, followed by a residency in pediatrics at Nemours and Thomas Jefferson University Hospital, where she served as chief resident. She subsequently trained in pediatric rheumatology at Nemours and Jefferson. She also earned a Master of Public Health from Temple University and studied chemistry at St. Joseph’s University. Recently, Leffler completed the Georgetown Executive Leadership Certification Program.

2 min

ChristianaCare Will Establish New Health Care Campus in Aston, Delaware County, Pennsylvania

ChristianaCare has announced that Aston, PA will be the location for its next health care campus that will feature a neighborhood hospital and a health center. This is one of two facilities that ChristianaCare plans to open in Delaware County, as announced in February 2024. The hospital will be built in partnership with Emerus Holdings, Inc., the nation’s leading developer of neighborhood hospitals. The ChristianaCare Aston Campus, located at 700 Turner Industrial Way, is expected to open in the second half of 2026. The site was chosen based on a market assessment of historical and projected demographic data and health care service availability as well as a consumer survey, community input and feedback from elected officials and business leaders. The study identified gaps in health care accessibility, concluding that Aston would be an ideal location for a health campus. “We are thrilled to be bringing high quality health care services to our neighbors in Aston in Delaware County,” said Jennifer Schwartz, chief strategy officer at ChristianaCare. “Our goal is to make access to health care easy, convenient and close to home in a way that is sustainable and right-sized to meet the needs of the local community.” The neighborhood hospital will operate 24/7 with approximately 10 inpatient beds and an emergency department. The emergency department will treat common emergency care needs such as falls, injuries, heart attacks and strokes. The hospital will also provide diagnostic capabilities, including ultrasound, computed tomography (CT), X-ray and laboratory services. In addition to on-site staff, the hospital will benefit from access to virtual consults — such as neurology and cardiology — to support safe and effective care. ChristianaCare will add a health center on the second floor of the hospital offering outpatient services. These services will be developed based on community needs and are expected to include primary and specialty care practices plus an array of other clinical services. The announcement comes as construction is already under way on ChristianaCare’s first Pennsylvania neighborhood hospital, in West Grove, nearby in southern Chester County, which is projected to open mid-2025. Together, these three new campuses represent a new layer of care coming to southeastern Pennsylvania. ChristianaCare has been providing health care services to the residents of southeastern Pennsylvania for many years. Today, ChristianaCare offers primary care in three Chester County practices that are located in Jennersville, West Grove and Kennett Square. In addition, Concord Health Center in Chadds Ford, Delaware County, provides a wide array of services, including primary care, women’s health, sports medicine, behavioral health and more. Combined, ChristianaCare is now the medical home for 25,000 residents in these communities.

2 min

Kert Anzilotti, M.D., Appointed President of the Medical Group of ChristianaCare

Kert Anzilotti, M.D., MBA, FACR has been appointed president of the Medical Group of ChristianaCare. Anzilotti has served as interim president since June 2024. He will also continue in his role as system chief medical officer of ChristianaCare. As president of the ChristianaCare Medical Group, Anzilotti will seek to improve every aspect of care for every person the Medical Group touches. He will focus on the optimization of care delivery, strategic visioning, network development, clinical technology implementation and leveraging medical informatics. Anzilotti will continue to develop new care models that transcend settings, promote value-based care and improve the patient experience across the clinical enterprise. Among his priorities are the adoption of population health measures, the embedding of health equity into care delivery and workforce development, further expansion of access points for patients and the continuous enhancement of patient and caregiver experience. “Dr. Anzilotti is exceptionally qualified to lead the Medical Group of ChristianaCare,” said Janice E. Nevin, M.D., MPH, president and CEO of ChristianaCare. “His passion for our mission and vision for the future strength of our Medical Group is unwavering. Since joining ChristianaCare in 2011, Dr. Anzilotti has earned a well-deserved reputation as a thoughtful and collaborative leader.” Anzilotti has served in numerous leadership roles at ChristianaCare, including as chief medical officer, acute care; chair of the Department of Radiology; medical director of Imaging Services; and physician leader of the Neurosciences Service Line. He also previously served as Interim President and CEO for the eBrightHealth ACO with responsibility for physician leadership and network operations. He is board certified in Neuroradiology. “Over the many years I have been at ChristianaCare, I have had the privilege of witnessing the dedication and compassion of my Medical Group colleagues as we served together with love and excellence,” Anzilotti said. “I am honored to lead this incredible, dynamic group that is reshaping the future of care, ensuring everyone we serve can achieve their best health.” Anzilotti earned his medical degree from Jefferson Medical College of Thomas Jefferson University in Philadelphia. He earned his MBA at the University of Delaware, completed the Managing Health Care Delivery Course at Harvard Business School and graduated as Physician Executive Fellow in the Health Management Academy, GE Fellows Program. The Medical Group of ChristianaCare consists of over 2,200 dedicated doctors, nurse practitioners, physician assistants and other caregivers. This highly skilled team delivers exceptional care through ChristianaCare’s community-based primary care and specialty care practices serving Delaware and surrounding states. Additionally, the Medical Group collaborates with ChristianaCare hospitalists to ensure seamless continuity of care for our patients, from primary care to hospital care and back again.

View all posts
Powered by